Institut for Klinisk Medicin

Infectious Diseases

Publikationer

Sortér efter: Dato | Forfatter | Titel

Bader-Larsen, K., Nielsen, B. U., Henriksen, E., Bryrup, T., Leo-Hansen, C., Mathiesen, I. H. M., Faurholt-Jepsen, D., Qvist, T., Oturai, P., Langdahl, B., Jeppesen, M., Olsen, H. V., Pressler, T., Skov, M. & Olsen, M. F. (2025). Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis. Clinical Nutrition, 54, 132-139. https://doi.org/10.1016/j.clnu.2025.09.008
Pedersen, O. S., Sperling, S., Lillebaek, T., Dahl, V. N. & Fløe, A. (2025). Borderline T-SPOT.TB results: test reliability, patient characteristics, and TB progression. International Journal of Tuberculosis and Lung Disease, 29(9), 422-424. https://doi.org/10.5588/ijtld.25.0178
Greenman, J. H., Moss, L., Chakraborty, S., Whitehead, B. J., Palmfedt, J., Nejsum, P., Hewitson, J. P. & Hitchcock, I. S. (2025). Brief report: Chronic murine schistosomiasis causes aberrant hemostasis. Experimental Hematology, 142, 104689. Artikel 104689. https://doi.org/10.1016/j.exphem.2024.104689
Toft, B. S., Rodkjær, L. Ø., Bekker, H., Nielsen, B. K. & Modrau, I. S. (2025). Cardiac surgery rehabilitation pathways and patient experiences: exploring gaps, challenges, and opportunities. European Journal of Preventive Cardiology, 32(Supplement 1). https://doi.org/10.1093/eurjpc/zwaf236.321
TransformCF Study Group (2025). Change in pulmonary pathogens 3 years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohort. Clinical Microbiology and Infection, 31(12), 2011-2017. https://doi.org/10.1016/j.cmi.2025.08.012, https://doi.org/10.1016/j.cmi.2025.08.012
Dahl, V. N., Fløe, A., Rudolf, F., van Ingen, J., Andersen, A. B., Wejse, C. M. & Lillebaek, T. (2025). Clinical characteristics and diagnostic practices in nontuberculous mycobacterial pulmonary disease: Insights from Denmark. Respiratory Medicine, 241, 108055. Artikel 108055. https://doi.org/10.1016/j.rmed.2025.108055
Larsen, C. S., Westergaard, C. L., Stærke, N. B., Arnet, U., Liu, G., Kantsø, L. R. & Kjellberg, J. (2025). Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark: A national registry study. Antiviral Therapy, 30(1). https://doi.org/10.1177/13596535241313244
Petersen, M. E., Khamas, A. B., Østergaard, L. J., Jørgensen, N. P. & Meyer, R. L. (2025). Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 69(4), Artikel e01483-24. https://doi.org/10.1128/aac.01483-24
Haglund, A., Stankovic, J., Christensen, T. D., Kristensen, L. & Lausch, K. R. (2025). Combined intracavitary, systemic antifungal and surgical treatment of Chronic Pulmonary Aspergillosis: experience from an immunocompromised patient. Medical Mycology Case Reports, 50, Artikel 100743. https://doi.org/10.1016/j.mmcr.2025.100743
Sørensen, L., Agergaard, J., Nielsen, T. B., Schiøttz-Christensen, B., Laursen, C. H., Leth, S., Nielsen, C. V. & Oestergaard, L. G. (2025). Construct validity of self-reported and interview-guided administration methods of the Danish version of the post-COVID-19 functional Status scale. Frontiers in Rehabilitation Sciences, 6, Artikel 1690892. https://doi.org/10.3389/fresc.2025.1690892

Viser resultater 101 til 110 ud af 2082

Forrige

7

8

9

10

11

12

13

14

15

16

Næste

Revideret 11.09.2025
-
Lotte Bjerregaard Snabe